Greater Sedentary Time Associated With Higher Risk for Alzheimer Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, May 16, 2025 -- Sedentary time is associated with an increased risk for Alzheimer disease (AD), according to a study published online May 13 in Alzheimer's & Dementia.
Marissa A. Gogniat, Ph.D., from the Vanderbilt Memory and Alzheimer's Center in Nashville, Tennessee, and colleagues examined how sedentary behavior relates to longitudinal brain structure and cognitive changes in older adults in a study involving 404 participants from the Vanderbilt Memory and Aging Project. Participants completed seven days of actigraphy, neuropsychological assessment, and 3 Tesla brain magnetic resonance imaging during a seven-year period. Sedentary time was examined in relation to brain structure and cognition.
The researchers found that greater sedentary time was associated with a smaller AD-neuroimaging signature and worse episodic memory in cross-sectional models. The associations varied based on apolipoprotein E ε4 status. Greater sedentary time related to faster hippocampal volume reductions and declines in naming and processing speed in longitudinal models.
“Our study showed that reducing sitting time could be a promising strategy for preventing neurodegeneration and subsequent cognitive decline," study coauthor Angela Jefferson, Ph.D., also from the Vanderbilt Memory and Alzheimer's Center, said in a press release. "This research highlights the importance of reducing sitting time, particularly among aging adults at increased genetic risk for Alzheimer's disease. It is critical to our brain health to take breaks from sitting throughout the day and move around to increase our active time.”
One author disclosed ties to Vivid Genomics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice
THURSDAY, May 15, 2025 -- Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant adverse events is similar to...
Apnea During REM May Affect Brain Regions Related to Memory Consolidation
TUESDAY, May 13, 2025 -- Greater obstructive sleep apnea (OSA)-related hypoxemia is associated with frontoparietal cerebrovascular pathology, which is linked to reduced medial...
No Negative Psychological Impact Seen for Disclosing Aβ Status
FRIDAY, May 9, 2025 -- Disclosure of amyloid-β (Aβ) status seems not have a negative psychological impact, according to a study published online May 7 in Alzheimer's...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.